益方生物科技（上海）股份有限公司2025年年度业绩预亏公告

Group 1 - The company anticipates a total profit loss of 291.82 million yuan for the year 2025, with a net profit attributable to the parent company expected to be -292.20 million yuan, and a net profit after deducting non-recurring gains and losses projected at -304.41 million yuan [3] - The expected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3] - The company reported a total profit loss of 240.20 million yuan for the year 2024, with a net profit attributable to the parent company also at -240.20 million yuan [5] Group 2 - The significant changes in performance for 2025 are primarily influenced by the intensity of research and development (R&D) investment and the composition of revenue [7] - The company is advancing multiple core clinical projects, including D-0502, D-2570, and D-0120, which are in various stages of clinical trials [7] - The company has made key progress in its preclinical pipeline with two innovative candidates, YF087 and YF550, showing promising anti-tumor potential [7][8] Group 3 - The company maintains high levels of R&D investment, but its current revenue mainly comes from licensing and collaboration, which varies from year to year [8] - The income from technology licensing and collaboration is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [8] - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [8]